Lakewood-Amedex says lead Bisphosphocin candidate Nu-3 posts Phase 2a diabetic foot ulcer trial data in Q1 2027
LABT•Lakewood-Amedex says topline data from Nu-3’s Phase 2a trial in mildly infected diabetic foot ulcers are expected in Q1 2027. The company also reported positive preclinical results for Bisphosphocin compounds in animal models of urinary tract and pulmonary infections.
1. Nu-3 trial timeline
Lakewood-Amedex says its Phase 2a trial of lead clinical candidate Nu-3 in mildly infected diabetic foot ulcers is underway, with topline data expected in Q1 2027.
2. Preclinical results
The company reported positive preclinical results for Bisphosphocin compounds in animal models of urinary tract and pulmonary infections. In rodent testing, Nu-8 reduced bacterial growth versus a vehicle control, while aerosol formulations showed activity in pulmonary infection models.
